X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6860) 6860
Publication (497) 497
Book Review (180) 180
Magazine Article (47) 47
Book Chapter (35) 35
Conference Proceeding (13) 13
Book / eBook (7) 7
Dissertation (5) 5
Web Resource (5) 5
Reference (2) 2
Data Set (1) 1
Government Document (1) 1
Presentation (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5488) 5488
male (2474) 2474
anti-inflammatory agents, non-steroidal - adverse effects (2347) 2347
female (2326) 2326
index medicus (2205) 2205
cyclooxygenase inhibitors - adverse effects (2195) 2195
animals (2020) 2020
celecoxib (1503) 1503
cyclooxygenase inhibitors - therapeutic use (1493) 1493
nonsteroidal antiinflammatory drugs (1461) 1461
middle aged (1372) 1372
anti-inflammatory agents, non-steroidal - therapeutic use (1284) 1284
aged (1215) 1215
cyclooxygenase 2 inhibitors - adverse effects (1189) 1189
adult (1167) 1167
cyclooxygenase 2 (1062) 1062
cox-2 inhibitors (1034) 1034
pharmacology & pharmacy (1024) 1024
risk factors (946) 946
cyclooxygenase 2 inhibitors (911) 911
membrane proteins (900) 900
cyclooxygenase 2 inhibitors - therapeutic use (853) 853
rheumatoid-arthritis (850) 850
sulfonamides - adverse effects (845) 845
cyclooxygenase inhibitors - pharmacology (834) 834
rats (768) 768
lactones - adverse effects (728) 728
cyclooxygenase 2 - metabolism (720) 720
cyclooxygenase-2 (714) 714
mice (678) 678
medicine, general & internal (666) 666
rofecoxib (658) 658
nonsteroidal anti-inflammatory drugs (638) 638
treatment outcome (629) 629
risk (603) 603
inflammation (593) 593
aspirin (582) 582
cyclooxygenase (575) 575
isoenzymes - antagonists & inhibitors (572) 572
double-blind method (568) 568
anti-inflammatory agents, non-steroidal - pharmacology (560) 560
sulfonamides - therapeutic use (559) 559
osteoarthritis (553) 553
cyclooxygenase inhibitors - administration & dosage (549) 549
sulfones - adverse effects (537) 537
aspirin - adverse effects (533) 533
dose-response relationship, drug (523) 523
cardiovascular diseases - chemically induced (477) 477
anti-inflammatory agents, non-steroidal - administration & dosage (473) 473
gastrointestinal toxicity (472) 472
double-blind (439) 439
prostaglandin-endoperoxide synthases (438) 438
cox-2 (424) 424
expression (420) 420
cyclooxygenase 2 inhibitors - pharmacology (418) 418
sulfones (416) 416
gastrointestinal diseases - chemically induced (410) 410
pyrazoles - adverse effects (408) 408
osteoarthritis - drug therapy (407) 407
pyrazoles (407) 407
research (406) 406
cyclooxygenase 2 inhibitors - administration & dosage (405) 405
prostaglandin-endoperoxide synthases - metabolism (402) 402
nsaids (396) 396
aged, 80 and over (389) 389
gastroenterology & hepatology (366) 366
drug therapy (365) 365
randomized controlled trials as topic (363) 363
lactones - therapeutic use (356) 356
cyclooxygenase inhibitors (341) 341
care and treatment (340) 340
pain (337) 337
arthritis, rheumatoid - drug therapy (336) 336
rheumatology (333) 333
time factors (333) 333
pain - drug therapy (329) 329
adolescent (324) 324
indomethacin (323) 323
prevention (321) 321
oncology (320) 320
prostaglandins (319) 319
inhibition (317) 317
drug therapy, combination (313) 313
surgery (310) 310
cyclooxygenase 2 - genetics (309) 309
sulfonamides - pharmacology (304) 304
clinical trials as topic (300) 300
drugs (292) 292
drug interactions (289) 289
pyrazoles - therapeutic use (289) 289
naproxen (286) 286
cancer (283) 283
prospective studies (283) 283
analysis (280) 280
risk assessment (280) 280
randomized controlled-trial (277) 277
disease models, animal (275) 275
immunology (275) 275
sulfonamides - administration & dosage (272) 272
health aspects (271) 271
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6329) 6329
German (168) 168
French (102) 102
Spanish (67) 67
Japanese (52) 52
Norwegian (32) 32
Swedish (31) 31
Dutch (27) 27
Russian (22) 22
Chinese (21) 21
Danish (20) 20
Polish (18) 18
Italian (15) 15
Finnish (11) 11
Hungarian (11) 11
Croatian (6) 6
Czech (5) 5
Hebrew (5) 5
Bulgarian (3) 3
Korean (2) 2
Portuguese (2) 2
Serbian (2) 2
Turkish (2) 2
Ukrainian (2) 2
Bosnian (1) 1
Lithuanian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
by Baigent, Colin and Bhala, N and Emberson, J and Merhi, A and Abramson, S and Arber, N and Baron, J.A and Bombardier, C and Cannon, C and Farkouh, M.E and FitzGerald, G.A and Goss, P and Halls, H and Hawk, E and Hawkey, C and Hennekens, C and Hochberg, M and Holland, L.E and Kearney, P.M and Laine, L and Lanas, A and Lance, P and Laupacis, A and Oates, J and Patrono, C and Schnitzer, T.J and Solomon, S and Tugwell, P and Wilson, K and Wittes, J and Adelowo, O and Aisen, P and Al-Quorain, A and Altman, R and Bakris, G and Baumgartner, H and Bresee, C and Carducci, M and Chang, D.-M and Chou, C.-T and Clegg, D and Cudkowicz, M and Doody, L and Miedany, Y.El and Falandry, C and Farley, J and Ford, L and Garcia-Losa, M and Gonzalez-Ortiz, M and Haghighi, M and Hala, M and Iwama, T and Jajic, Z and Kerr, D and Kim, H.-S and Kohne, C and Koo, B.-K and Martin, B and Meinert, C and Muller, N and Myklebust, G and Neustadt, D and Omdal, R and Ozgocmen, S and Papas, A and Patrignani, P and Pelliccia, F and Roy, V and Schlegelmilch, I and Umar, A and Wahlstrom, O and Wollheim, F and Yocum, S and Zhang, X.Y and Hall, E and McGettigan, P and Midgley, R and Moore, R.A and Philipson, R and Curtis, S and Reicin, A and Bond, J and Moore, A and Essex, M and Fabule, J and Morrison, B and Tive, L and Bhala, N and Davies, K and Emberson, J and Halls, H and Holland, L.E and Kearney, P.M and Merhi, A and Patrono, C and Wilson, K and Yau, F and Coxib Traditional NSAID Trialists and Coxib and traditional NSAID Trialists' (CNT) Collaboration
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9894, pp. 769 - 779
Journal Article
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 12/2016, Volume 375, Issue 26, pp. 2519 - 2529
BACKGROUND The cardiovascular safety of celecoxib, as compared with nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), remains uncertain. METHODS... 
MEDICINE, GENERAL & INTERNAL | PAIN | METAANALYSIS | OSTEOARTHRITIS | CLINICAL-TRIAL | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | Celecoxib - adverse effects | Naproxen - adverse effects | Ibuprofen - therapeutic use | Humans | Middle Aged | Male | Risk | Celecoxib - therapeutic use | Naproxen - therapeutic use | Cyclooxygenase 2 Inhibitors - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Arthritis - drug therapy | Cyclooxygenase 2 Inhibitors - therapeutic use | Intention to Treat Analysis | Kidney Diseases - chemically induced | Cardiovascular Diseases - mortality | Female | Aged | Cardiovascular Diseases - chemically induced | Ibuprofen - adverse effects | Gastrointestinal Diseases - chemically induced | Care and treatment | Safety and security measures | Naproxen | Ibuprofen | Dosage and administration | Arthritis | Celecoxib | Diagnosis | Cardiovascular diseases | Risk factors | Cardiovascular disease | Side effects | Nonsteroidal anti-inflammatory drugs | Pain management | Myocardial infarction | Fees & charges | Hemorrhage | Pain | Motivation | Analgesics | Safety | Drug dosages | Cerebral infarction | Statistical analysis | Anemia | Committees | FDA approval | Patients | Manuscripts | Rheumatoid arthritis | Collaboration | Osteoarthritis | Pharmaceuticals
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9573, pp. 1621 - 1626
Summary Background Guidelines on pain management recommend that patients at risk of ulcers receive either a cyclo-oxygenase (COX 2) inhibitor or a... 
Internal Medicine | ESOMEPRAZOLE | MEDICINE, GENERAL & INTERNAL | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | NSAID | CYCLOOXYGENASE-2 INHIBITORS | ARTHRITIS PATIENTS | NAPROXEN | COMPLICATIONS | HELICOBACTER-PYLORI | PEPTIC-ULCER | CELECOXIB | Pyrazoles - therapeutic use | Humans | Esomeprazole - adverse effects | Male | Secondary Prevention | Osteoarthritis - drug therapy | Esomeprazole - therapeutic use | Peptic Ulcer Hemorrhage - prevention & control | Female | Drug Therapy, Combination | Pyrazoles - adverse effects | Anti-Ulcer Agents - therapeutic use | Double-Blind Method | Proton Pump Inhibitors | Risk Factors | Anti-Ulcer Agents - adverse effects | Peptic Ulcer Hemorrhage - chemically induced | Treatment Outcome | Celecoxib | Peptic Ulcer Hemorrhage - therapy | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Sulfonamides - adverse effects | Aged | Cyclooxygenase Inhibitors - adverse effects | Cyclooxygenase Inhibitors - therapeutic use | Prevention | Complications and side effects | COX-2 inhibitors | Relapse | Gastrointestinal bleeding | Peptic ulcer | Proton pump inhibitors | Dosage and administration | Drug therapy | Diseases | Drugs | Medical research | Physical examinations | Hospitals | Analgesics | Ulcers | Terminal illnesses | Clinical trials | Pharmaceuticals
Journal Article
Circulation, ISSN 0009-7322, 06/2006, Volume 113, Issue 25, pp. 2906 - 2913